Published in FEBS Lett on November 12, 1990
Agents that increase the permeability of the outer membrane. Microbiol Rev (1992) 7.52
Peptide antibiotics. Antimicrob Agents Chemother (1999) 5.76
Crystallization of antimicrobial pores in membranes: magainin and protegrin. Biophys J (2000) 2.41
Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides. Proc Natl Acad Sci U S A (2008) 2.35
Structure and orientation of the antibiotic peptide magainin in membranes by solid-state nuclear magnetic resonance spectroscopy. Protein Sci (1993) 2.16
In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother (1999) 2.10
Mechanisms of antimicrobial, cytolytic, and cell-penetrating peptides: from kinetics to thermodynamics. Biochemistry (2009) 1.72
Solid-state NMR investigation of the membrane-disrupting mechanism of antimicrobial peptides MSI-78 and MSI-594 derived from magainin 2 and melittin. Biophys J (2006) 1.70
Two-dimensional 1H NMR experiments show that the 23-residue magainin antibiotic peptide is an alpha-helix in dodecylphosphocholine micelles, sodium dodecylsulfate micelles, and trifluoroethanol/water solution. J Biomol NMR (1997) 1.66
A quantitative model for the all-or-none permeabilization of phospholipid vesicles by the antimicrobial peptide cecropin A. Biophys J (2007) 1.64
Interaction of antimicrobial peptide protegrin with biomembranes. Proc Natl Acad Sci U S A (2003) 1.61
Soft X-ray tomography of phenotypic switching and the cellular response to antifungal peptoids in Candida albicans. Proc Natl Acad Sci U S A (2009) 1.41
Magainin 2 revisited: a test of the quantitative model for the all-or-none permeabilization of phospholipid vesicles. Biophys J (2009) 1.40
Antimicrobial peptides. Pharmaceuticals (Basel) (2013) 1.37
Orientation and dynamics of an antimicrobial peptide in the lipid bilayer by solid-state NMR spectroscopy. Biophys J (2001) 1.27
Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob Agents Chemother (2005) 1.25
Augmentation of the antibacterial activity of magainin by positive-charge chain extension. Antimicrob Agents Chemother (1992) 1.25
Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Proc Natl Acad Sci U S A (1996) 1.17
Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. Antimicrob Agents Chemother (2008) 1.11
P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob Agents Chemother (2001) 1.08
Short alkylated peptoid mimics of antimicrobial lipopeptides. Antimicrob Agents Chemother (2010) 1.08
Antimicrobial peptoids are effective against Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2011) 1.07
In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob Agents Chemother (2004) 1.04
Synthetic peptides of human lysosomal cathepsin G with potent antipseudomonal activity. Infect Immun (1993) 1.03
Human salivary mucin MUC7 12-mer-L and 12-mer-D peptides: antifungal activity in saliva, enhancement of activity with protease inhibitor cocktail or EDTA, and cytotoxicity to human cells. Antimicrob Agents Chemother (2005) 1.02
Oncolytic activities of host defense peptides. Int J Mol Sci (2011) 1.00
Peptide design for antimicrobial and immunomodulatory applications. Biopolymers (2013) 0.99
Computational studies of protegrin antimicrobial peptides: a review. Peptides (2010) 0.97
Membrane insertion and bilayer perturbation by antimicrobial peptide CM15. Biophys J (2007) 0.97
Efficacy of antimicrobial peptoids against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 0.93
Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimetic. Proc Natl Acad Sci U S A (2013) 0.93
De-novo design of antimicrobial peptides for plant protection. PLoS One (2013) 0.91
Database-Guided Discovery of Potent Peptides to Combat HIV-1 or Superbugs. Pharmaceuticals (Basel) (2013) 0.90
Multifunctional enveloped mesoporous silica nanoparticles for subcellular co-delivery of drug and therapeutic peptide. Sci Rep (2014) 0.90
Antimicrobial peptides and induced membrane curvature: geometry, coordination chemistry, and molecular engineering. Curr Opin Solid State Mater Sci (2013) 0.89
Androctonin, a hydrophilic disulphide-bridged non-haemolytic anti-microbial peptide: a plausible mode of action. Biochem J (2000) 0.85
Peptides and Peptidomimetics for Antimicrobial Drug Design. Pharmaceuticals (Basel) (2015) 0.85
An antimicrobial peptidomimetic induces Mucorales cell death through mitochondria-mediated apoptosis. PLoS One (2013) 0.85
Identification of a novel lytic peptide for the treatment of solid tumours. Genes Cancer (2014) 0.85
Unimolecular study of the interaction between the outer membrane protein OmpF from E. coli and an analogue of the HP(2-20) antimicrobial peptide. J Bioenerg Biomembr (2010) 0.85
Characterization of antibiotic peptide pores using cryo-EM and comparison to neutron scattering. Biophys J (2009) 0.84
Dual-targeting pro-apoptotic peptide for programmed cancer cell death via specific mitochondria damage. Sci Rep (2013) 0.84
Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis. Antimicrob Agents Chemother (2013) 0.84
Design and surface immobilization of short anti-biofilm peptides. Acta Biomater (2016) 0.84
Isolation and characterization of diverse antimicrobial lipopeptides produced by Citrobacter and Enterobacter. BMC Microbiol (2013) 0.83
Mechanisms mediating bactericidal properties and conditions that enhance the potency of a broad-spectrum oligo-acyl-lysyl. Antimicrob Agents Chemother (2010) 0.83
Improvement of the efficacy of linear undecapeptides against plant-pathogenic bacteria by incorporation of D-amino acids. Appl Environ Microbiol (2011) 0.83
A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion. Proc Natl Acad Sci U S A (1998) 0.82
Fluorine: a new element in protein design. Protein Sci (2012) 0.82
Current and potential applications of host-defense peptides and proteins in urology. Biomed Res Int (2015) 0.80
Structure-antimicrobial activity relationship between pleurocidin and its enantiomer. Exp Mol Med (2008) 0.78
Roles of d-Amino Acids on the Bioactivity of Host Defense Peptides. Int J Mol Sci (2016) 0.77
Structure-activity relationships of the human prothrombin kringle-2 peptide derivative NSA9: anti-proliferative activity and cellular internalization. Biochem J (2006) 0.76
Design of a functionally equivalent nonglycosylated analog of the glycopeptide antibiotic formaecin I. Protein Sci (2007) 0.75
D-Amino Acid Substitution of Peptide-Mediated NF-κB Suppression in mdx Mice Preserves Therapeutic Benefit in Skeletal Muscle, but Causes Kidney Toxicity. Mol Med (2015) 0.75
Analysis of the flexibility and stability of the structure of magainin in a bilayer, and in aqueous and nonaqueous solutions using molecular dynamics simulations. J Mol Model (2015) 0.75
Oligomerization of the antimicrobial peptide Protegrin-5 in a membrane-mimicking environment. Structural studies by high-resolution NMR spectroscopy. Eur Biophys J (2016) 0.75
Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother (1989) 4.04
Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and v-erbB protein. Cell (1985) 4.02
CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature (1994) 3.70
Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med (1995) 1.99
The binding site of acetylcholine receptor as visualized in the X-Ray structure of a complex between alpha-bungarotoxin and a mimotope peptide. Neuron (2001) 1.96
Total synthesis of the structural gene for the precursor of a tyrosine suppressor transfer RNA from Escherichia coli. 1. General introduction. J Biol Chem (1976) 1.91
Use of a ribosomal RNA gene probe for the epidemiological study of methicillin and ciprofloxacin resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (1990) 1.65
Comparison of polyclonal antiserum versus monoclonal antibodies for the rapid diagnosis of influenza A virus infections by immunofluorescence in clinical specimens. J Clin Microbiol (1985) 1.65
Antigenicity and immunogenicity of an intracellular delivery system of major histocompatibility complex class I epitopes that bypasses proteasome processing. J Immunother (2001) 1.41
The diagnostic and therapeutic approach to acute bronchiolitis in hospitalized children in Israel: a nationwide survey. Isr Med Assoc J (2000) 1.40
A survey of current Israeli practices and approach to partially treated meningitis in children. Isr J Med Sci (1995) 1.39
Enhancement of phagocytosis - a newly found activity of substance P residing in its N-terminal tetrapeptide sequence. Biochem Biophys Res Commun (1980) 1.39
New look at Bloch's law for contrast. J Opt Soc Am A (1986) 1.35
Tuftsin (an Ig-associated tetrapeptide) triggers the immunogenic function of macrophages: implications for activation of programmed cells. Proc Natl Acad Sci U S A (1978) 1.33
Nosocomial acinetobacter meningitis secondary to invasive procedures: report of 25 cases and review. Clin Infect Dis (1993) 1.28
Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria. J Med Chem (2000) 1.25
Augmentation of the antibacterial activity of magainin by positive-charge chain extension. Antimicrob Agents Chemother (1992) 1.25
Antibodies to synthetic peptides as probes for the binding site on the alpha subunit of the acetylcholine receptor. Proc Natl Acad Sci U S A (1985) 1.25
N-terminal modifications of Polymyxin B nonapeptide and their effect on antibacterial activity. Peptides (2001) 1.14
Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J (2005) 1.14
Tryptophan residues of cholera toxin and its A and B protomers. Intrinsic fluorescence and solute quenching upon interacting with the ganglioside GM1, oligo-GM1, or dansylated oligo-GM1. J Biol Chem (1981) 1.14
MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol (1999) 1.13
Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1986) 1.12
In vitro antibacterial activities of antibiotics against Pseudomonas aeruginosa in peritoneal dialysis fluid. Antimicrob Agents Chemother (1985) 1.12
An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J Pharmacol Exp Ther (1991) 1.09
Structure-function studies of cholera toxin and its A and B protomers. Modification of tryptophan residues. J Biol Chem (1981) 1.09
Effect of inoculum size on antimicrobial susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis (1993) 1.08
A beta -hairpin structure in a 13-mer peptide that binds alpha -bungarotoxin with high affinity and neutralizes its toxicity. Proc Natl Acad Sci U S A (2001) 1.07
Tuftsin and some analogs: synthesis and interaction with human polymorphonuclear leukocytes. Biochim Biophys Acta (1977) 1.06
Analysis of ligand binding to the synthetic dodecapeptide 185-196 of the acetylcholine receptor alpha subunit. Proc Natl Acad Sci U S A (1986) 1.05
Decreased tuftsin concentrations in patients who have undergone splenectomy. Br Med J (1977) 1.05
The functional association of polymyxin B with bacterial lipopolysaccharide is stereospecific: studies on polymyxin B nonapeptide. Biochemistry (2000) 1.05
Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J Pharmacol Exp Ther (1998) 1.04
High and low potency interferon-alpha subtypes induce (2'-5') oligoadenylate synthetase with similar efficiency. Virology (1983) 1.03
Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature (1993) 1.03
Structure-function studies of amphiphilic antibacterial peptides. J Med Chem (1993) 1.02
Insulin-like effects of vanadium: basic and clinical implications. J Inorg Biochem (2000) 1.01
Monofunctional substrates of polynucleotide phosphorylase. The monoaddition of 2'(3')-O-isovaleryl-nucleoside diphosphate to an initiator oligonucleotide. Eur J Biochem (1971) 1.01
Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res (1992) 1.00
Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exp Ther (1995) 1.00
Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist. Endocrinology (1989) 1.00
A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses. Proc Natl Acad Sci U S A (1997) 0.99
Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci U S A (1999) 0.99
Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain. Int J Cancer (2000) 0.99
Q fever endocarditis in Israel and a worldwide review. Scand J Infect Dis (1997) 0.99
Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci U S A (1996) 0.99
Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome. Proc Natl Acad Sci U S A (1985) 0.98
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res (2000) 0.98
Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother (1986) 0.97
Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis (2004) 0.97
Radioimmunoassay of the phagocytosis-stimulating peptide tuftsin in normal and splenectomized subjects. Eur J Immunol (1977) 0.97
Peptides generated from C-reactive protein by a neutrophil membrane protease. Amino acid sequence and effects of peptides on neutrophil oxidative metabolism and chemotaxis. J Immunol (1990) 0.95
A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc Natl Acad Sci U S A (1993) 0.95
The effect of Tuftsin on the nitrous blue tetrazolium reduction of normal human polymorphonuclear leukocytes. J Clin Invest (1975) 0.95
Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J Clin Invest (1994) 0.95
Activity of two synthetic amphiphilic peptides and magainin-2 against herpes simplex virus types 1 and 2. Int J Pept Protein Res (1994) 0.94
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J Neural Transm (Vienna) (2004) 0.94
Concentrations of ciprofloxacin in human liver, gallbladder, and bile after oral administration. Eur J Clin Pharmacol (1987) 0.93
IL-2 induces T cell adherence to extracellular matrix: inhibition of adherence and migration by IL-2 peptides generated by leukocyte elastase. J Immunol (1998) 0.93
Serum amyloid A binds specific extracellular matrix glycoproteins and induces the adhesion of resting CD4+ T cells. J Immunol (1996) 0.93
Use of trityl- and -naphthylcarbamoylcellulose derivatives in oligonucleotide synthesis. Biochemistry (1973) 0.92
Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res (1996) 0.92
Design and synthesis of peptides that bind alpha-bungarotoxin with high affinity. Chem Biol (2001) 0.92
Binding of C-reactive protein to human neutrophils. FEBS Lett (1987) 0.92
Inhibition of cell adhesion to glycoproteins of the extracellular matrix by peptides corresponding to serum amyloid A. Toward understanding the physiological role of an enigmatic protein. Eur J Biochem (1994) 0.91
Enhanced repopulation of murine hematopoietic organs in sublethally irradiated mice after treatment with ciprofloxacin. Blood (1991) 0.91
Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. Peptides (1997) 0.90
Synergistic action of amphotericin B and rifampin against Rhizopus species. Antimicrob Agents Chemother (1987) 0.90
Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2. Proc Natl Acad Sci U S A (2001) 0.90
Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Invest (1997) 0.90
Anti-acetylcholine receptor response achieved by immunization with a synthetic peptide from the receptor sequence. Biochem Biophys Res Commun (1984) 0.90
VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury. J Mol Neurosci (2000) 0.90
Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis. Proc Natl Acad Sci U S A (1996) 0.89
Cross resistance to ciprofloxacin and other antimicrobial agents among clinical isolates of Acinetobacter calcoaceticus biovar anitratus. Antimicrob Agents Chemother (1990) 0.89
Two carriers for motion perception: color and luminance. Vision Res (1991) 0.88
VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J Mol Neurosci (2000) 0.88
Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. Am J Med (1987) 0.88
Effect of serum amyloid A on selected in vitro functions of isolated human neutrophils. J Lab Clin Med (1998) 0.88
Concentration of norfloxacin in human gallbladder tissue and bile after single-dose oral administration. Antimicrob Agents Chemother (1987) 0.87
A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. Brain Res (1991) 0.87
Maternal and fetal serum and tissue levels of ceftriaxone following preoperative prophylaxis in emergency cesarean section. Chemotherapy (1993) 0.87
Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides (1991) 0.87
A novel approach for a water-soluble long-acting insulin prodrug: design, preparation, and analysis of [(2-sulfo)-9-fluorenylmethoxycarbonyl](3)-insulin. J Med Chem (2000) 0.87
VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res Treat (2001) 0.87
Gonadotropin-releasing hormone in milk. Science (1977) 0.86
Altered peptide ligands of a myasthenogenic epitope as modulators of specific T-cell responses. Scand J Immunol (1996) 0.86
Modulation of human neutrophil function by C-reactive protein. Eur J Biochem (1987) 0.86
The hydrolysis of p-nitrophenylacetate in water. Mechanism and method of measurement. Eur J Biochem (1974) 0.86
Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. J Neurobiol (1997) 0.86
Risk factors for sternal wound infection in children undergoing cardiac surgery: a case-control study. J Hosp Infect (2008) 0.85
Self and foreign 60-kilodalton heat shock protein T cell epitope peptides serve as immunogenic carriers for a T cell-independent sugar antigen. J Immunol (1995) 0.85
Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Ann N Y Acad Sci (1994) 0.85
Tuftsin, Thr-Lys-Pro-Arg. Anatomy of an immunologically active peptide. Mol Cell Biochem (1981) 0.85